Business Wire6d
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less TM gastric balloon for weight loss, the Allurion ...
Morningstar6d
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the Allurion ...
Allurion Shares Surge 185% Following $7.4 Million Fundraising Announcement
Shares of Allurion Technologies ( ALUR, Financials) surged 185% to $10.54 in midday trading after the company announced plans ...
Stockhouse6d
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, ...
Investing9d
Allurion secures new patent for gastric balloon technology
The U.S. Patent and Trademark Office granted Patent No. 12,209,677, which pertains to advancements in Allurion's proprietary Balloon technology, particularly improving the precision of the valve ...
Le Lézard7d
Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
The Allurion Gastric Balloon is an investigational device in ... Potential in the $16 Billion Coronavirus Market SAN DIEGO, CA / ACCESS Newswire / January 27, 2025 / Ainos, Inc. ("Ainos ...
Investing7d
Allurion announces study on obesity treatment enhancement
The study will explore the combination of the Allurion Program, including the Allurion Balloon and Virtual Care Suite, with GLP-1 agonists to potentially improve muscle mass retention and overall body ...